Wockhardt plans to clear debt, fund antibiotic trials with QIP funds. Khorakiwala expects revenue growth, EBITDA rise, and completion of global antibiotic trial for innovations like WCK5222 and WCK4873.
Copyright © 2024 | WordPress Theme by MH Themes